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Abstract: Cryptococcal meningitis remains a significant opportunistic infection among HIV-infected
patients, contributing 15–20% of HIV-related mortality. A complication of initiating antiretroviral
therapy (ART) following opportunistic infection is immune reconstitution inflammatory syndrome
(IRIS). IRIS aﬄicts 10–30% of HIV-infected patients with cryptococcal meningitis (CM), but its
immunopathogenesis is poorly understood. We compared circulating T cell memory subsets and
cytokine responses among 17 HIV-infected Ugandans with CM: 11 with and 6 without CM-IRIS.
At meningitis diagnosis, stimulation with cryptococcal capsule component, glucuronoxylomannan
(GXM) elicited consistently lower frequencies of CD4+ and CD8+ T cell memory subsets expressing
intracellular cytokines (IL-2, IFN-γ, and IL-17) among subjects who subsequently developed CM-IRIS.
After ART initiation, T cells evolved to show a decreased CD8+ central memory phenotype. At
the onset of CM-IRIS, stimulation more frequently generated polyfunctional IL-2+/IL-17+ CD4+ T
cells in patients with CM-IRIS. Moreover, CD8+ central and effector memory T cells from CM-IRIS
subjects also demonstrated more robust IL-2 responses to antigenic stimulation vs. controls. Thus,
ART during CM elicits distinct differences in T cell cytokine production in response to cryptococcal
antigens both prior to and during the development of IRIS, suggesting an immunologic foundation
for the development of this morbid complication of CM infection.
Keywords: cryptococcal meningitis; Cryptococcus; HIV; CD4 T cells; CD8 T cells; adaptive immune
response; IRIS
1. Introduction
Cryptococcal meningitis causes 15–20% of AIDS-related mortality worldwide [1]. In sub-Saharan
African countries with high HIV prevalence (>5%), Cryptococcus is the most common cause of meningitis
in adults, accounting for 26% of cases in Malawi, 45% in Zimbabwe, 30% in South Africa [2–5], and
60% in Uganda [3,5,6]. In 2014, an estimated 162,500 cases of cryptococcal meningitis (CM) occurred
J. Fungi 2019, 5, 42; doi:10.3390/jof5020042 www.mdpi.com/journal/jof
J. Fungi 2019, 5, 42 2 of 15
in sub-Saharan Africa resulting in more than 90,000 deaths [1]. Despite improved immune function
in antiretroviral therapy (ART)-treated HIV-infected patients in low and middle-income countries, a
significant proportion of patients with a new HIV diagnosis still present with advanced disease (CD4+
T cells < 200/µL) and are at risk for opportunistic infections (OI) such as cryptococcal meningitis [7].
ART suppresses HIV replication and CD4+ T cell loss by apoptosis allowing immune reconstitution
to occur. However, in addition to its benefits, immune reconstitution with ART can also be detrimental.
A proportion of patients treated with ART experience a constellation of symptoms and signs in which
sub-clinical or pre-existing infections trigger an exaggerated inflammatory response that leads to
clinical deterioration, presenting as immune reconstitution inflammatory syndrome (IRIS) [8]. IRIS can
present as unmasking or paradoxical phenomena. In unmasking IRIS, subclinical infections become
overtly symptomatic with a first episode of the OI after ART initiation. Conversely, in paradoxical IRIS,
there is usually evidence of initial microbiological and clinical response to treatment of the OI pre-ART,
which evolves into the recrudescence of symptoms following ART without microbiological evidence of
the associated OI following ART initiation.
Depending on the site and activity, IRIS can present with a range of symptoms from minor to
severe inflammation resulting in organ failure, hospitalization, or death [9–12]. Whether the current
shift to a ‘Test & Treat’ ART strategy with limited screening and treatment of OIs prior to ART will
increase the incidence of unmasking IRIS remains to be seen. Reversal of CD4+ T cell lymphopenia and
increased T cell activation have been associated with the development of IRIS [13]. Studies in vitro
have demonstrated that attenuated Cryptococcus-specific IFN-γ responses prior to starting ART are
associated with cryptococcal meningitis-IRIS when patients who developed CM-IRIS were compared
to HIV-infected controls who did not develop IRIS [14]. However, the ontogeny of antigen-specific T
cell responses prior to and during cryptococcal IRIS are not well defined.
We have previously demonstrated that lower levels of inflammation, demonstrated by decreased
numbers of CSF leukocytes and levels of CSF protein, IFN-γ, IL-6, IL-8, and TNF-α were predictors
for developing cryptococcal IRIS [15]. It is imperative that the mechanisms underlying cryptococcal
IRIS are understood in order to prevent or optimize interventions against the deleterious effects of
cryptococcal IRIS. We hypothesized that prior to ART initiation, T cell phenotype and function would
distinguish patients who subsequently did and did not later develop paradoxical cryptococcal IRIS.
We, therefore, investigated the quantitative and functional reconstitution of CD4+, CD8+ T cells,
characterizing the association of T cell responses with the development or absence of cryptococcal IRIS
in HIV-infected patients receiving ART after cryptococcal meningitis treatment in order to understand
the contribution of these components to the immunopathogenesis of cryptococcal IRIS.
2. Materials and Methods
2.1. Study Subjects and Procedures
As previously described [16], we sequentially screened participants presenting with suspected
meningitis at Mulago National Referral Hospital in Kampala, Uganda. We enrolled adults with a first
episode of CM diagnosed by cerebrospinal fluid (CSF) cryptococcal antigen or positive Cryptococcus
neoformans culture [17]. Participants received amphotericin B (0.7–1 mg/kg/day) for 2 weeks with oral
fluconazole (800 mg/day) which was continued for ~5 weeks, then later decreased to 400 mg/day for
8 weeks and 200 mg/day thereafter [18]. ART (zidovudine, lamivudine, and efavirenz) was started
within 6 weeks of CM diagnosis [19].
We collected blood from subjects longitudinally with the isolation of peripheral blood mononuclear
cells (PBMCs) by density centrifugation gradient (Ficoll 1077, Sigma) followed by cryopreservation in
RPMI-1640 with fetal bovine serum (20%), dimethyl sulphoxide (10%), and penicillin/streptomycin,
1%) in liquid nitrogen.
A diagnosis of definite/probable/possible CM-IRIS was made according to the published consensus
case definition [8], with external adjudication by a three-physician panel whose members were not
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part of the clinical team. Grading was classified as definite, probable, or possible IRIS based on the
available clinical and CSF information. Institutional review board approvals were obtained from the
School of Medicine Ethics review committee at Makerere University (REF 2009–022) and the University
of Minnesota (0810M49622), and written informed consent was obtained.
2.2. PBMC Stimulation and Surface Flow Cytometric Staining
Cryopreserved PBMCs at initial CM diagnosis, during CM-IRIS and from control subjects without
CM-IRIS matched for ART duration were thawed and stimulated in vitro. PBMCs were rapidly thawed
and diluted in complete media (RPMI-1640 with 10% FBS, 2% HEPES, 2% l-Glutamine, 1% Pen/Strep)
and 1 × 106 cells were added to each of three wells. Glucuronoxylomannan (GXM) was added to the
test well with co-stimulatory anti-CD28 and anti-49d monoclonal antibodies to enhance the detection
of cytokine-secreting T cells. Staphylococcal enterotoxin B (SEB; 10 ng/mL) (Invivogen, France), a
non-specific polyclonal activator, was used as the positive control and phosphate buffered saline (PBS)
(100 µL/well) (Sigma-Aldrich, USA) as the negative control. After 2 hours of incubation in 5% carbon
dioxide at 37 ◦C, Brefeldin A (100 µL/mL) (BD, Golgi Stop, catalog # 554724) was added to each well
(to inhibit intracellular transport, allowing for the accumulation of cytokines in the Golgi complex) and
cells were incubated for another 4 hours then refrigerated in the dark overnight at 4 ◦C.
We assessed in vitro cytokine responses to cryptococcal GXM in circulating T cells at CM diagnosis,
at the time of CM-IRIS, or a matched ART time point for CM controls without IRIS. We stained cells with
commercial monoclonal antibodies reactive with CD45ROPerCPCy5.5 (clone UCHL1, BD Biosciences),
CD27APC-H7 (clone MT271, BD Biosciences), CD3V500 (clone UCHT1, BD Biosciences), and CD4V450
(clone RPA-T4, BD Horizon). CD3+CD4− cells were considered as CD8+ T cells. We assessed T
cell activation using the proportion of T cells expressing HLA-DRPECy7 (clone LN3, BD Biosciences).
We prepared fluorescence minus one (FMO) controls on blood samples to set gates for CD27 and
CD45RO. Following the selection of single cells based on FSC height vs. FSC area, differential gating
of lymphocytes was based on size and granularity (Figure 1). T cell phenotype, activation state,
and percentage of T cell subsets were determined by 8-color flow cytometry using a FACSCanto II
(BD Biosciences).J. Fungi 2019, 5, x FOR PEER REVIEW 4 of 15 
 
 
Figure 1. Flow cytometry gating strategy for T cells. Multiparameter flow cytometry was used to 
identify the frequency, phenotype, and post-stimulation cytokine expression of CD4+ and CD8+ T cells 
within total peripheral blood mononuclear cells of patients with and without CM-IRIS at baseline and 
at the CM-IRIS event. Representative staining shows the analytic gating strategy: (A) FSC-H/FSC-A 
showing the singlet gate; (B) FSC/SSC for lymphocytes selected from singlet gate; (C) T cells 
expressing CD3 were selected; (D) CD3+ cells expressing CD4 and CD8 were then identified; (E) 
gating by differential expression of CD27 and CD45RO identified naïve and memory T cells subsets 
with naive T cells as (CD27+CD45RO-); central memory as (CD27+CD45RO+), effector memory as 
(CD27-CD45RO+), and terminally differentiated effector memory as (CD27-CD45RO-); (F) CD4+ 
expression of IL-17 (unstimulated); (G) representative example of IL-2 expression by CD4+ T cells 
(unstimulated); (H) representative example of IFN-γ expression by CD4+ T cells (unstimulated); (I) 
Figure 1. Cont.
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Figure 1. Flow cytometry gating strategy for T cells. Multiparameter flow cytometry was used
to identify the frequency, phenotype, and post-stimulation cytokine expression of CD4+ and CD8+
T cells within total peripheral blood mononuclear cells of patients with and without CM-IRIS at
baseline and at the CM-IRIS event. Representative staining shows the analytic gating strategy: (A)
FSC-H/FSC-A showing the singlet gate; (B) FSC/SSC for lymphocytes selected from singlet gate; (C) T
cells expressing CD3 were selected; (D) CD3+ cells expressing CD4 and CD8 were then identified; (E)
gating by differential expression of CD27 and CD45RO identified naïve and memory T cells subsets
with naive T cells as (CD27+CD45RO−); central memory as (CD27+CD45RO+), effector memory as
(CD27−CD45RO+), and terminally differentiated effector memory as (CD27−CD45RO−); (F) CD4+
expression of IL-17 (unstimulated); (G) representative example of IL-2 expression by CD4+ T cells
(unstimulated); (H) representative example of IFN-γ expression by CD4+ T cells (unstimulated); (I)
representative example of HLA-DR expression by CD4+ T cells and; (J) HLA-DR Fluorescence minus
one gating; (K) representative example of IFN-γ expression by CD4+ T cells in a subject with CM-IRIS
and; (L) IFN-γ expression by CD4+ T cells in a control subject without CM-IRIS.
2.3. Intracellular Cytokine Staining
We determined T cell cytokine responses by intracellular cytokine staining. Following 6 hours of
stimulation at 37 ◦C and overnight incubation at 4 ◦C, cells were washed, fixed and permeabilized with
successive washes in FACS Permeabilizing Solution (BD Biosciences) and stained with intracellular
monoclonal antibodies reactive with IFN-γPE (clone 4S.B3, Biolegend), and IL-17Alexa647 (clone SPCL
1362, BD Biosciences) and IL-2FITC (clone 5433.111, BD Biosciences). One million events were acquired
the following day using an 8-color FACS Canto II (BD Biosciences), and data were analyzed using
FlowJo version 10.0.5 (TreeStar, USA).
2.4. Statistical Analysis
Data were analyzed using GraphPad Prism, version 6.0b (GraphPad Software Inc., CA, USA) and
Spice, version 5.35 (NIAID, NIH, Bethesda, MD, USA). We compared paired samples at meningitis
diagnosis and at CM-IRIS event using the non-parametric Wilcoxon signed-rank test. We compared
cell phenotype and activation variables between CM-IRIS and time-matched controls using the
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non-parametric Mann-Whitney rank sum test. Statistical significance was defined as a p-value ≤ 0.05.
We compared cytokine expression profiles by permutation analysis to determine combinations of
cytokine expression following background subtraction, using a 10,000-iteration Monte Carlo simulation
model described in detail elsewhere [20].
3. Results
Among 11 HIV-1-infected adults who developed CM-IRIS cases, cryopreserved PBMCs were
available from 10 at CM diagnosis and 11 at the time of CM-IRIS event. Among the six HIV-1-infected
control subjects with CM but no IRIS, PBMC were available from five at the time of the CM diagnosis
and all at a subsequent visit time-matched to the timing of CM-IRIS in the other group (67 vs. 78 days).
Age, baseline CD4 and CD8 T cell counts, cryptococcal antigen (CrAg) titer, HIV viral load,
CSF protein, and white blood cells were similar among subjects with CM-IRIS vs. controls
(Table 1). At meningitis diagnosis, subjects who subsequently developed CM-IRIS showed higher but
non-significant quantitative CSF Cryptococcus colony forming units (CFU) on culture, median 213,796
(IQR: 91,201–288,403) CFU/mL compared to control subjects who did not develop IRIS median 9332
(IQR: 281–181,970) CFU/mL.
Table 1. Characteristics of subjects who developed cryptococcal meningitis (CM)-immune reconstitution
inflammatory syndrome (IRIS) vs. subjects without CM-IRIS.
Controls (n = 6) CM-IRIS (n = 11) p-Value
Men, N (%) 1 (17%) 8 (73%) 0.05
Age, years 35 (28, 40) 35 (29, 42) 0.937
CD4+ T cells/µL-Diagnosis 8 (5, 166) 6.5 (4, 28) 0.828
- >3 month on ART 156 (55, 309) 68 (33, 79) 0.256
CD8+ T cells/µL-Diagnosis 163 (97, 784) 256 (140, 591) 0.515
- >3 month on ART 1005 (615, 1086) 831 (565, 997) 0.463
Plasma HIV RNA (log10 copies/mL) 5.1 (4.6, 5.2) 5.3 (4.8, 5.6) 0.260
CSF Cryptococcus (log10 CFU/mL) 3.97 (2.45, 5.26) 5.33 (4.96, 5.46) 0.078
CSF CRAG titer, 1:x 4512 (528, 12192) 7200 (4048, 16384) 0.455
CSF protein (mg/dL) 60 (47, 68) 53 (20, 70) 0.471
CSF WBC/µL 20 (<5, 45) <5 (<5, <5) 0.169
Duration from ART initiation (days) 67 (48, 92) 78 (43, 202) 0.737
Values listed as median (IQR) or mean (±SD). Values are at the time of cryptococcal meningitis diagnosis unless
otherwise stated. Abbreviations: ART-Antiretroviral Therapy; CRAG-Cryptococcal Antigen; CSF-Cerebrospinal
Fluid; CFU-colony forming units; HIV-Human immunodeficiency virus.
3.1. T Cell Phenotype and Activation at CM Diagnosis vs. Controls
At CM diagnosis, circulating CD4+ T cell numbers were similarly very low in both groups. The
frequencies of total CD8+ T cells were comparable. Central memory CD4+ T cells (CD27+CD45RO+)
and naive CD8+ T cells (CD27+CD45RO−) were the predominant T cell subsets (Figure 2) without
significant differences in T cell subsets between groups. Similarly, baseline activation of CD4+ T cells
expressing HLA-DR was very high at baseline but comparable among subjects with future CM-IRIS vs.
controls, 81% (IQR: 66, 90) vs. 72% (IQR: 46, 80), (p = 0.196), respectively. Further, CD8 T cell activation,
also high, did not differ, with frequencies of 91% IQR: 85, 95) vs. 94% (IQR: 59, 98), (p = 0.853) in the
two groups, respectively.
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Figure 2. Frequencies of CD4+ and CD8+ memory T cell subsets at the time of initial cryptococcal
meningitis diagnosis among ART-naïve subjects who later developed CM-IRIS vs. controls without
IRIS. CD4+ Central memory and CD8+ naïve T cells predominated without significant differences
between groups. Bars represent median values and error bars show interquartile ranges. Abbreviations:
TDEM- terminally differentiated effector memory. White bars represent CM diagnosis, red bars
represent CM-IRIS.
3.2. T Cell Cytokine Responses at Baseline
At baseline, the frequencies of CD4+ and CD8+ memory subset T cells expressing intracellular
cytokines (IL-2, IFN-γ, and IL-17) after GXM stimulation we e consistently lower among subjects who
later developed CM-IRIS (Table 2) for ach subset and each intracellular cytokine. Unstimulated and
SEB stimulation did not demonstrat significant differences in respons s.
Table 2. Cytokine responses by T cell phenotype among subjects with CM-IRIS vs. controls following
GXM stimulation at CM diagnosis.
Controls (n = 5) CM-IRIS (n = 10) p-Value
CD4+ T cells
Central memory (TCM)
IFN-γ+ 6 (3, 11) 0.8 (0, 3) 0.005
IL-2+ 5 (2, 22) 1 (0.1, 3) 0.012
IL-17+ 2 (1, 6) 0.5 (0, 2) 0.054
Effector memory (TEM)
IFN-γ+ 8 (4, 16) 0.5 (0, 3) 0.027
IL-2+ 3 (2, 13) 0 (0, 0.1) 0.004
IL-17+ 2 (1.9, 3) 0 <0.001
Terminally differentiated effector memory (TTDEM)
IFN-γ+ 3 (1, 16) 0 (0, 0.4) 0.005
IL-2+ 74 (12, 86) 0 <0.001
IL-17+ 0.1 (0, 1.1) 0 (0, 2) 0.624
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Table 2. Cont.
Controls (n = 5) CM-IRIS (n = 10) p-Value
CD8+ T cells
Central memory (TCM)
IFN-γ+ 2.4 (2.2, 3.1) 0.4 (0.1, 0.5) <0.001
IL-2+ 1.1 (0.5, 2.1) 0.07 (0.03, 0.3) 0.005
IL-17+ 1.2 (0.9, 1.4) 0.08 (0.02, 0.2) 0.003
Effector memory (TEM)
IFN-γ+ 6.2 (3.1, 9.9) 0.7 (0.2, 1.5) 0.005
IL-2+ 1.2 (0.5, 1.7) 0.01 (0, 0.1) <0.001
IL-17+ 1.2 (1.0, 1.3) 0.06 (0, 0.2) <0.001
Terminally differentiated effector memory (TTDEM)
IFN-γ+ 1.3 (0.6, 3.5) 0.3 (0.2, 0.9) 0.037
IL-2+ 1.1 (0.3, 1.2) 0.03 (0, 0.6) 0.068
IL-17+ 0.09 (0.08, 0.25) 0.01 (0, 0.17) 0.119
Figures are presented as percentages of T cells. P-values obtained by Mann Whitney U test. Data are presented as
median (Interquartile Range). Significant P values are in bold typeface.
3.3. Cytokine Responses at CM-IRIS vs. Controls
Upon correcting for the cytokine expression in unstimulated samples, we found that
mitogen-induced IL-2 responses by total CD8+ (p = 0.034) (Figure 3A) and naïve CD8+ T cells
(p = 0.020) (Figure 3B) were significantly elevated among patients with CM-IRIS compared with
controls, while there was a trend for higher CD8+ TDEM T cell IL-2 responses among subjects with
CM-IRIS compared with controls (p = 0.061) (Figure 3C). These results suggest that T cells are primed
to increase IL-2 expression during CM-IRIS. This could result either in expanding the number and
function of GXM-specific T cell clones or could be an effect of IL-2 inhibiting T cell proliferation
during CM-IRIS.
3.4. Phenotype and Cytokine Responses among Subjects with Paired Samples at CM Diagnosis vs. CM-IRIS
We compared phenotype and cytokine expression at CM diagnosis and during CM-IRIS from
10 subjects with paired samples. CD4+ T cell frequency was significantly higher at CM-IRIS, 8%
(IQR, 4–13%) compared to CM diagnosis, 3% (IQR, 1–3%) (p = 0.014). At CM-IRIS, the frequency of
CD4+ T cells expressing HLA-DR was significantly decreased compared to CM diagnosis, 66% (IQR,
60%–79%) vs. 81% (IQR, 66%–90%), (p = 0.014) respectively. CD4+ T cells with a central memory
phenotype expressing IL-17 were less frequent at CM-IRIS compared with CM diagnosis following
GXM stimulation (Supplementary Figure S1). In contrast, without GXM stimulation, CD4+ T cells
with effector phenotype expressing IL-2 were more frequent at CM-IRIS compared to CM diagnosis,
0.92% (IQR, 0%–2.4%) vs. 0%, (p = 0.016), respectively (Figure 3). No differences were observed in the
frequency of CD4+ TCM cells expressing IFN-γ on stimulation with GXM.
3.5. CD4+ and CD8+ T Cell Polyfunctional Cytokine Responses at CM-IRIS
Upon stimulation with GXM, subjects at the time of IRIS CM-IRIS more frequently expressed
dual-functional IL-2+IL-17+IFN-γ− CD4+T cells vs. controls (0.34% vs. 0.02%; p = 0.010) (Figure 4).
When we compared CD8+ T cell responses at CM-IRIS vs. controls, mono-functional IL-2+IL-17−IFN-γ−
CD8+ T cells were more frequent at CM-IRIS, 0.6% (IQR: 0.2, 1.0) compared to controls, 0.05% (IQR:
0.0, 0.1), p = 0.01 (Supplementary Figure S2). These data confirm the increased immune CD4+ T cell
responses with co-expression of IL-2/IL-17 and CD8+ T cells expressing IL-2 during CM-IRIS thereby
contributing to the immunopathogenesis of this syndrome.
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Figure 4. Peripheral blood mononuclear cells from subjects with cryptococcal meningitis were 
stimulated with Glucuronoxylomannan (GXM). Intracellular Interleukin-2 (IL-2), IL-17 and 
Interferon-γ (IFN-γ) expression by CD4+ T cells was quantified using flow cytometry. The bar chart 
shows each of the three possible combination responses on the x-axis. The percentage of the total 
cytokine response is shown on the y-axis, with the filled bar representing the interquartile range and 
a black line at the median. Statistically significant differences (p < .05) by rank-sum testing are 
indicated by the plus sign. Responses from ART matched control subjects who did not develop CM-
IRIS are shown in blue, responses from subjects with CM-IRIS are in red on the bar graph. The pie 
charts show the fractions according to the pie-slice colors shown at the bottom of the bar chart, with 
color-coded arcs indicating the contributions of IL-2 (yellow), IFN-γ (black), and IL-17 (cyan) to the 
3-, 2- and 1-function responses. Statistical comparisons of the overall responses by permutation testing 
are shown in the pie category test result chart where the red represents IL-2+IL-17+IFN-γ+ CD4+ T cells; 
yellow represents IL-2+IL-17+IFN-γ- CD4+T cells; black represents IL-2+IL-17-IFN-γ+ CD4+ T cells; green 
Figure 4. Peripheral blo d mono l ll f jects ith cryptococcal me ingitis w re
stimulated with Glucuronoxyl mannan (GXM). Intracellul r Interleukin-2 (IL-2), IL-17 and Interferon-γ
(IFN-γ) xpression by CD4+ T cells was quantified u ing flow cytometry. The bar chart shows each of
the three possible combinati n responses on the x-axis. The percent ge of the total cytokine response
is shown on the y-axi , with the filled bar representing the int rquartile ra ge and a black li e at
the median. St tistically signific nt differences (p < 0.05) by rank-sum testing are indicated by the
plus sign. Responses from ART matched control subjects who did not develop CM-IRIS are shown
in blue, responses from subjects with CM-IRIS are in red on the bar graph. The pie charts show the
fractions according to the pie-slice colors shown at the bottom of the bar chart, with color-coded arcs
indicating the contributions of IL-2 (yellow), IFN-γ (black), and IL-17 (cyan) to the 3-, 2- and 1-function
responses. Statistical comparisons of the overall responses by permutation testing are shown in the pie
category test result chart where the red represents IL-2+IL-17+IFN-γ+ CD4+ T cells; yellow represents
IL-2+IL-17+IFN-γ− CD4+T cells; black represents IL-2+IL-17−IFN-γ+ CD4+ T cells; green represents
IL-2+IL-17−IFN-γ− CD4+ T cells; cyan represents IL-2−IL-17+IFN-γ+ CD4+ T cells; blue represents
IL-2−IL-17+IFN-γ− CD4+ T cells and purple represents IL-2−IL-17−IFN-γ+ CD4+ T cells. Patients with
CM-IRIS had a significantly elevated proportion of duo functional IL-2+IL-17+IFN-γ− CD4+T cells
compared with matched Controls following GXM stimulation.
In summary, patients who developed CM-IRIS exhibited aberrant CD4+ T cell responses during
the primary CM episode as demonstrated by their poor mitogenic and GXM-specific IL-2 responses.
Notably, patients who developed CM-IRIS had diminished IFN-γ+ CD4+ T cells responsive to GXM
at baseline and this response was markedly different at CM-IRIS. CM-IRIS was associated with
robust dual-functional CD4+IL-2+IL-17+, CD8+IL-2+, and CD8+IL-17+ T cell responses. The selective
expansion of these GXM-specific T cells is consistent with other studies of T cell responses during
IRIS [13], which confirms exaggerated Th1 and Th17 responses during IRIS.
4. Discussion
Cryptococcal IRIS remains a clinical challenge in populations where advanced HIV disease
persists and yet the precise immunopathogenic mechanisms remain unclear. The phenotype of CD4+
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T cell effector memory responses to Cryptococcus is associated with disease severity and outcome
in HIV-associated cryptococcal meningitis [21]. We found that at baseline, those who subsequently
developed CM-IRIS showed a characteristically lower immune response with decreased CD4+IFN-γ+
T cells and poor CD8+IL-17+ mitogenic responses at CM-IRIS. Indeed, during CM-IRIS, this pattern
shifted to exhibit robust CD8+IL-2+ and CD4+IL-2+IL-17+IFN-γ− T cell responses to GXM, which
also distinguished them from the non-IRIS patients. We found no association between T cell memory
phenotype and the incidence of CM-IRIS.
Antigen-specific immune responses during CM-IRIS have been rarely studied. Most studies
have looked at the expression of cytokines in blood or CSF but not the source of these cytokines. An
instructive feature of this study was the detection of the cytokines expressed by T cells at the single cell
level before and during cryptococcal IRIS.
To understand why some patients presenting with cryptococcal meningitis subsequently develop
CM-IRIS after initiating ART, we evaluated the immune response to cryptococcal antigen. The
high-molecular-mass capsular polysaccharide, glucuronoxylomannan, is found in high titers in
patients with disseminated cryptococcosis [22,23]. The host response to GXM involves a granulomatous
inflammatory response, intact cell-mediated immunity, and a Th1 pattern of cytokine release. GXM
has anti-phagocytic properties and inhibits leukocyte migration and proliferation [24,25] and could
explain the significantly diminished baseline immune response among patients who subsequently
developed CM-IRIS. This diminished immune response could predispose to subsequent IRIS events
resulting from failure to completely clear the antigen burden, which sets the stage for a possible over
exaggerated response as hypothesized by Barber and colleagues when CD4 T cell recovery delivers the
missing IFN-γ stimulus to partially activated macrophages that subsequently become fully activated
en masse with a resulting ‘cytokine storm’ [26].
Consistent with this suppressive activity by GXM, participants who developed CM-IRIS could
have had a high fungal burden at CM diagnosis (although not statistically significant) when compared
to control subjects, suggesting that the presence of persistent antigen when immune reconstitution is
initiated may underlie, in part, the development of IRIS. This finding is consistent with data showing
that patients with disseminated cryptococcal fungemia have a six-fold higher risk of subsequently
developing IRIS due to the high fungal burden and poor clearance. Similarly, patients with a
cryptococcal antigen titer >1:1024 are reported to show an increased risk of IRIS [27]. These findings
are also consistent with data showing that in the CSF of patients infected with C. neoformans, the
pro-inflammatory cytokines IL-6, TNF-α, and IFN-γ were inversely correlated with cryptococcal fungal
burden [28].
Murine models suggest that late cryptococcal clearance is impaired in the absence of IL-17 and, in
a cohort of HIV-infected Ugandans, IL-17 was significantly lower in those who developed CM-IRIS
compared with controls prior to ART initiation [29,30]. It is therefore plausible that more robust
immune responses during the primary cryptococcal infection induced cryptococcal clearance and
mitigated the risk of CM-IRIS among controls who had no IRIS.
It is also possible that patients who developed CM-IRIS had aberrant or dysregulated CD4+ T cell
function during the primary cryptococcal infection resulting in persistent cryptococcal antigen, known
to be a risk factor for CM-IRIS [27,31]. These findings are consistent with a study suggesting that robust
CD4+ T cell responses during IRIS represent a dysregulated response against residual antigen [13].
This aberrant function appears to result in poor immune responses during the primary cryptococcal
infection and subsequently in dysregulated robust T cell responses characteristic of IRIS. This T cell
dysfunction could also explain the poor inflammatory response observed in the CSF of patients who
developed CM-IRIS in a Ugandan cohort [15].
Interferon-γ plays an important role in the host defense against intracellular pathogens including
Cryptococcus neoformans at the site of infection and has been studied as adjunctive therapy against
cryptococcal meningitis [22,32]. At CM diagnosis, we found decreased frequencies of CD4+ IFN-γ+ T
cells in patients who developed CM-IRIS compared with controls similar to the lower IFN-γ responses
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induced by cryptococcal mannoprotein in a cohort of patients with CM in Durban [14]. It should be
noted that the cytokine responses in the Durban cohort were measured in whole blood cultures and
not by intracellular flow cytometry at single cell level.
The differential gene expression between patients who develop CM-IRIS and those who do not
has been demonstrated previously in a Ugandan cohort of HIV-infected patients. The most common
molecular and cellular functions of the up-regulated genes were cell proliferation, cell apoptosis, and
immune response (antigen presentation, innate responses, and inflammatory responses) [33]. More
recent data from a Durban cohort suggests that CM-IRIS occurring within 12 weeks of ART initiation was
predicted by the low expression of interferon-inducible genes, whereas late CM-IRIS events, occurring
after 12 weeks of ART were characterized by abnormal upregulation of transcripts expressed in T, B, and
natural killer cells such as IFNG, IL27, and LRB1 [34]. In addition to immunoactive cytokines, Yoon et al.
have also demonstrated significantly low plasma levels of IgM, Lam-binding IgM, Lam-binding IgG, and
GXM-IgG among patients who developed CM-IRIS [35]. Together, these data suggest the involvement of
genetic, innate, and adaptive (T and B cell) mechanisms in the development of CM-IRIS.
Interleukin-2 has a dual role in the regulation of the immune system. On one hand, IL-2 is
involved in the activation of the immune system by promoting the proliferation of lymphocytes,
macrophages, and natural killer cells, as well as aiding in the differentiation of CD4 T cells [36]. On the
other hand, IL-2 works to regulate the immune system through regulatory T cells, thus, inhibiting T
cell proliferation. In the current study, GXM-induced CD4+ T cells expressing IL-2 were significantly
elevated among participants at the time of CM-IRIS compared with controls. This immune response
appeared to be driven by the naïve and terminally differentiated memory CD4+ T cells.
Similarly, we found significantly elevated CD4+ effector memory T cells expressing IL-17 among
those with CM-IRIS compared with controls matched for ART duration. The differential expression of
these cytokines in response to GXM suggests an exaggerated GXM-specific response among patients
with CM-IRIS. This response could induce other pro-inflammatory cytokines that contribute to the
immunopathology occurring at CM-IRIS. Indeed, a distinctive feature of CM-IRIS was the quality
of the immune response at CM-IRIS compared to controls where we found significant elevation
of dual-function CD4+IL-2+IL-17+ and monofunctional CD8+ IL-2+ T cells compared with controls
without IRIS. This finding is consistent with data showing elevated IL-2 and IL-17 among subjects with
CM-IRIS compared to time-matched controls in a cohort of HIV-infected Ugandans [30]. IL-2 and IL-17
have been implicated in promoting protective immune responses against Cryptococcus [29,37] in murine
models. Thus, the differential expression of GXM-induced IL-2 and IL-17 among participants with
CM-IRIS suggests that these two cytokines are involved in the immunopathogenesis of CM-IRIS. During
CM-IRIS, IL-2 could play the role of inducing immune activation and driving the inflammatory process
that is measurable in CSF. The Th17 differentiation factor, IL-6 is associated with IRIS [38–40] and
inhibits T regulatory cell proliferation in favor of Th17 cell induction in the presence of TGF-β [41,42].
IL-17 is known to induce tissue inflammation and could also induce the inflammation observed during
CM-IRIS [41]. IL-2 expression by CD8+ T cells was not elevated during TB-IRIS [43]. Although not
specific to which cell type was expressing the cytokines, a study involving patients with pneumocystis,
Histoplasma, Mycobacterium avium, and cryptococcal IRIS found similar elevation of IL-2 and IL-17 in
plasma prior to and during the IRIS event compared to controls without IRIS [44], suggesting that our
findings are not unique to cryptococcal IRIS.
The small sample size and low T cell counts preclude firm conclusions on differences between T
cell phenotypes, markers of T cell activation and some of the cytokine responses among subjects with
and without CM-IRIS. The ideal compartment to study would have been the CSF; however, due to the
limited number of cells available in CSF and the challenge of obtaining CSF from ART-time matched
controls, in vitro stimulation studies were performed with peripheral blood and are only reflective of
the immune response in the periphery rather than the local immune response in the central nervous
system, where CM-IRIS symptoms occur.
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We only evaluated T cell responses against GXM. Approximately 90% of the cryptococcal cell wall
is comprised of GXM [45]. Thus, the T cell responses in this study may not be reflective of what occurs
in vivo where responses against other cryptococcal capsular antigens including galactoxylomannan
and mannoproteins may be dissimilar. It is also possible that the cellular and cytokine responses
we observed with CM-IRIS may represent a more natural or healthy response to this pathogen as
the subjects’ immune function was restored following ART. We did not evaluate T regulatory cells,
which would have given a broader picture of the adaptive immune response and the balance between
pro-inflammatory and anti-inflammatory pathways, which are now thought to contribute to fungal
IRIS [46]. Larger prospective studies are needed to concurrently examine T cell responses against
various cryptococcal antigens in both CSF and peripheral blood prior to ART initiation, after patients
initiate ART and at CM-IRIS events.
In conclusion, cryptococcal IRIS after ART initiation occurs as a consequence of both host and
pathogen factors. Aberrant T cell function during the primary cryptococcal infection observed
in our study could have contributed to the pathogenesis of CM-IRIS. The elevated expression of
GXM-specific IL-2 during CM-IRIS may indicate GXM-specific T cell proliferation during the IRIS
event. These responses occurring in the enclosed CNS may be detrimental, resulting in the subsequent
immunopathology associated with cryptococcal IRIS.
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